Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
We believe the two primary factors in Carasent’s equity story in 2026 are organic growth and scaling up adj. EBITDAC margins. On the organic growth side, we believe Carasent has ample opportunities in continuing to onboard new customers, as well as upselling to existing users. Furthermore, we believe the launch of the surgical module for Webdoc will drive new customer inflows. With regard to adj. EBITDAC, we believe Carasent will be able to keep its operating expenditure and capitalised development costs relatively flat Y/Y, which coupled with a gross margin of ~85%, results in our view of favourable operating leverage and should enable the company to raise margins, we believe.
Long term
6+ YEARS
We believe Carasent should be able to post solid growth over the longer term thanks to its competitive products and still relatively low penetration of ~13% in Sweden (its largest market). Furthermore, after the acquisition of Data-Al in Germany and the upcoming launch of Webdoc X there, Carasent has increased its growth runway markedly by adding ~SEK8bn of addressable market. Moreover, we believe continued efforts to expand the use-case of current products (such as the surgical module and Medsum) could contribute to long-term growth for the company. With a net cash position, we believe Carasent is well-positioned for capital allocation going forward.
Failure to comply with regulatory requirements could impede the company’s ability to market its products.
Healthcare data is highly sensitive, and a cyber-attack could be damaging for Carasent.
Carasent primarily targets private healthcare clinics, meaning any political reforms limiting or prohibiting private healthcare would affect the company.
Price
Fair range high value
Fair range low value
Upper end: Organic growth accelerates on the back of VGR, Germany, and Stockholm, leading to higher growth and margins than we anticipate. Lower end: Margin uptake is more sluggish than anticipated due to higher-than-expected opex growth.
We use a medium-term approach in our valuation methodology, where we discount 2028e sales (end of financial target period) back to today. The low end of our fair value range is derived by applying an EV/sales of 4.5x, ~30% below the 10-year average NTM EV/sales multiple of Nordic software peers, whereas at the top end of our fair value range we apply an EV/sales of 6x, the three-year NTM average of its peer group, and discount that back to today using a WACC of 10%.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB